newsfilter
← Latest News
GlobeNewswire·

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

—Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 —Streamlining operations and focusing on delivering potential value